The main takeaway from the House Energy and Commerce Committee hearing on HHS's 2023 budget was that biosimilars were not mentioned as much as they should have been, said Julie M. Reed of the Biosimilars Forum.
The main takeaway from the House Energy and Commerce Committee hearing on HHS's 2023 budget was that biosimilars were not mentioned as much as should have been, said Julie M. Reed, the executive director of the Biosimilars Forum.
Transcript
For those who missed it, what were some of the highlights from the House Energy and Commerce Committee hearing regarding the HHS budget for fiscal year 2023?
I think the highlights of that hearing mostly were, from a Biosimilars Forum perspective, it's what we didn't hear. We didn't hear enough about how HHS is going to do more to gain cost savings using biosimilars. How they're going to do more policies that we've been advocating for for years, [addressing] market barriers and improving access to biosimilars.
So, I think that was the most surprising thing for the Biosimilar Forum and our members. We heard a little bit about biosimilars. We've been saying, "Look, there's a solution right here to reduce prescription drug cost overall." It's such a critical, critical year for biosimilars, especially with the 7 biosimilars for Humira [adalimumab] launching next year.
So, we're going to go back and ask HHS to continue to support biosimilars and continue to work with them, especially on those upcoming launches. So, that was our takeaway, and it's now a greater priority for the Forum to get back to HHS.
Challenges and Guidance in Biosimilar Assessment: An ISPOR Report on HTA Agency Approaches
May 14th 2024The ISPOR report highlights the urgent need for clear guidance on when and how to conduct health technology assessments (HTAs) for biosimilars, emphasizing the challenges faced by HTA agencies and the evolving role of HTAs in evaluating biosimilar value.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.